Blog
Thymosin alpha-1: what the large TESTS sepsis trial found
Immune mechanisms need testing against outcomes that matter to patients. The paper concerns a specific clinical setting, not certification of a shop product.
Evidence discussed: Randomized phase 3 human trial.
What the researchers studied
The TESTS trial assessed thymosin alpha-1 in adults with sepsis across multiple centers in China. Its primary endpoint was death from any cause within 28 days. Mortality was similar in treatment and placebo groups, without a significant main-comparison difference. [1]
How to interpret the result
A negative primary result should not be replaced by general immunity-boosting claims. The participants were critically ill; the study cannot define effects in healthy users or benefits for unrelated infections.
What readers can take from it
Immune mechanisms need testing against outcomes that matter to patients. The paper concerns a specific clinical setting, not certification of a shop product.
This original editorial summary provides no diagnosis, dosing or treatment advice. The study did not test or certify a PeptiKing product.
Sources
[1] Wu et al., TESTS phase 3 sepsis trial (2025). PMID: 39814420. Based on the PubMed-indexed abstract and record; full-text methods were not independently reviewed.
[2] TESTS correction notice (2025). PMID: 40447307. PubMed links this correction to the primary trial. The correction text must be checked during full-text editorial review.